Affimed N.V. (AFMD - Free Report) was a big mover last session, as the company saw its shares rise more than 10% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This breaks the recent trend of the company, as the stock is now trading above the volatile price range of $1.45 to $5.55 in the past one-month time frame.
The stock was driven after the company has entered into a collaboration agreement with Genentech to build up Novel NK cell engager-based immunotherapeutics to treat cancer.
The company has seen a mixed track record when it comes to estimate revisions of one increase and one decrease over the past month, while the Zacks Consensus Estimate for the current quarter has remained unchanged. The recent price action is encouraging though, so make sure to keep a close watch on this firm in the near future.
Affimed currently has a Zacks Rank #3 (Hold), while its Earnings ESP is 0.00%.
A better-ranked stock in the Medical - Drugs industry is BioSpecifics Technologies Corp. (BSTC - Free Report) , which currently has a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Is AFMD going up? Or down? Predict to see what others think: Up or Down
Best Electric Car Stock? You'll Never Guess It.
Zacks Research has released a report that may shock many investors. One stock stands out as the best way to invest in the surge to electric cars. And it's not the one you may think!
Much like petroleum 150 years ago, lithium battery power is set to shake the world, creating millionaires and reshaping geo-politics. Soon electric vehicles (EVs) may be cheaper than gas guzzlers. Some are already reaching 265 miles on a single charge. With battery prices plummeting and charging stations set to multiply, revenues that were already at $31 billion in 2016 are expected to blast to over $67 billion by the end of 2022.
See Zacks Best EV Stock Free >>